Treats Attention-Deficit/Hyperactivity Disorder (ADHD). ANDA 90609, held by Dr Reddys. Atomoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 90609 (Atomoxetine Hydrochloride), held by Dr Reddys, was first approved by FDA on Feb 23, 2018, with 2 approved supplements and 0 published complete response letters.
Atomoxetine hydrochloride is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). 1.1 Attention-Deficit/Hyperactivity Disorder (ADHD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 23, 2018 | Original application | Approved | None posted |
| Atomoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 18MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 25MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 40MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 60MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 80MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 100MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| May 26, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 26, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 23, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters